Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.
暂无分享,去创建一个
P Tugwell | B Combe | G. Koch | P. Tugwell | C. Bombardier | M. Dougados | G. Wells | D. Felson | Hyon K. Choi | F. Wolfe | D. M. van der Heijde | M. Boers | H. Paulus | K. Michaud | V. Strand | R. Landewé | T. Pincus | M. Ward | P. Emery | M. Weinblatt | P. V. van Riel | J. Smolen | J. O'dell | S. Bombardieri | D. Heijde | E. Martı́n-Mola | G. Wells | L. Simon | M. Matucci-Cerinic | J. Smolen | B. Combe | T. Kvien | T. Sokka | D. Aletaha | G. Koch | Bin Zhang | J. Gómez-Reino | R. V. van Vollenhoven | M. Weinblatt | J. Bathon | A. Zink | B. White | E. Keystone | T. Kvien | J. Gómez-Reino | P. Richards | B. White | T Pincus | T Sokka | C Bombardier | D van der Heijde | T K Kvien | M Dougados | M Boers | H Paulus | P Emery | D Felson | D Aletaha | R. Vollenhoven | S. Vlad | A Zink | F Wolfe | Bin Zhang | G Wells | V Strand | S Bombardieri | B. Zhang | T. Karonitsch | R Landewe | E Martin-Mola | M Matucci-Cerinic | G Koch | L Simon | T Karonitsch | J Bathon | H Choi | J Gomez-Reino | E Keystone | K Michaud | J O'Dell | P Richards | J Siegel | J S Smolen | P van Riel | S Vlad | R van Vollenhoven | M Ward | M Weinblatt | B White | B Zhang | J. Siegel | H. Choi | P. Riel | R. V. Vollenhoven | J. O’dell | D. V. D. Heijde | Hyon K. Choi
[1] M. Prevoo,et al. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. , 1996, British journal of rheumatology.
[2] C. Bombardier,et al. Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders. , 2007, The Journal of rheumatology.
[3] A. Zwinderman,et al. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. , 1999, Arthritis and rheumatism.
[4] Désirée van der Heijde,et al. A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. , 2007, Arthritis and rheumatism.
[5] J J Anderson,et al. The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials , 1993 .
[6] L. Kiemeney,et al. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. , 2001, Arthritis and rheumatism.
[7] H. Kautiainen,et al. Nottingham health profile questionnaire incorporates important aspects of the patient perspective into outcome assessment in rheumatoid arthritis. , 2008, Clinical and experimental rheumatology.
[8] P. Tugwell,et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. , 1994, The Journal of rheumatology. Supplement.
[9] E. Taal,et al. Incorporating the patient perspective into outcome assessment in rheumatoid arthritis--progress at OMERACT 7. , 2005, The Journal of rheumatology.
[10] M. Uffmann,et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score , 2005, Arthritis research & therapy.
[11] F Guillemin,et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees , 2004, Annals of the rheumatic diseases.
[12] M. Dougados,et al. Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis , 2008, Annals of the rheumatic diseases.
[13] J J Anderson,et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. , 1995, Arthritis and rheumatism.
[14] R N Maini,et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. , 2005, Arthritis and rheumatism.
[15] M. A. van 't Hof,et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. , 1990, Annals of the rheumatic diseases.
[16] Michael M Ward,et al. Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. , 2006, Arthritis and rheumatism.
[17] P. Tugwell,et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. , 2003, Rheumatology.
[18] G. Koch,et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations , 2008, Annals of the rheumatic diseases.